stockrowPulmonx Corporation
LUNG Healthcare Medical Devices
Pulmonx Corporation’s revenue for fiscal 2025 (year ended December 2025) was $90.5 million, up 8.01% from fiscal 2024.
- Revenue
- +6.20%
- EPS
- +42.8%
- Free cash flow
- +61.3%
- Total debt
- +1.57%
Quarter to September 2026, against a year earlier
Follow LUNG
Alert me
Pulmonx Corporation (LUNG) EV/Sales
As of 5 November 2026, Pulmonx Corporation (LUNG) trades at a EV/Sales of 1.1×. Over the past ten years it has ranged from 0.2× (August 2025) to 44.8× (April 2021); the current reading is higher than 24% of that period. That is below the Medical Devices industry median of 2.7× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.6× | (73.74%) |
| FY2024 | 2.4× | (59.04%) |
| FY2023 | 5.9× | 104.32% |
| FY2022 | 2.9× | (86.09%) |
| FY2021 | 20.6× | 37.64% |
| FY2020 | 15.0× | 318.23% |
| FY2019 | 3.6× | 0.00% |
| FY2018 | 3.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 0.8× | 81.03% |
| Jun 2026 | 0.4× | 25.64% |
| Mar 2026 | 0.3× | (47.06%) |
| Dec 2025 | 0.6× | 116.76% |
| 25 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CATX Perspective Therapeutics, Inc. compare | −339× |
| NYXH Nyxoah SA compare | 0.1× |
| QTRX Quanterix Corporation compare | 0.3× |
| OWLT Owlet, Inc. compare | 0.9× |
| LUNG Pulmonx Corporation | 1.1× |
| ZOMDF Zomedica Corp. compare | 1.3× |
| MXCT MaxCyte, Inc. compare | 1.3× |
| APYX Apyx Medical Corporation compare | 2.5× |
| LUCD Lucid Diagnostics Inc. compare | 11.3× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)